Revista Colombiana de Reumatologia最新文献

{"title":"Progressive pulmonary fibrosis associated autoimmune diseases: Systematic review of the literature","authors":"Luis Javier Cajas Santana ,&nbsp;Diana Rocío Gil Calderón ,&nbsp;Manuela Rubio Rivera ,&nbsp;José Alex Yate ,&nbsp;Javier Leonardo Galindo","doi":"10.1016/j.rcreu.2023.09.007","DOIUrl":"10.1016/j.rcreu.2023.09.007","url":null,"abstract":"<div><h3>Introduction</h3><p>Connective tissue disease-related interstitial lung disease (CTD-ILD) accounts for 30% of all cases of ILD. Some patients progress and develop progressive pulmonary fibrosis, which has a prognosis comparable to interstitial pulmonary fibrosis. In this study, relevant evidence about epidemiology, risk factors, biomarkers, and treatment are reviewed.</p></div><div><h3>Materials and methods</h3><p>A systematic review of the literature was carried out. Original observational and descriptive articles were included. Articles not providing information about the CTD diagnosis were excluded. PUBMED, EMBASE, SCOPUS, and LILACS were all searched. The total number of articles obtained was 528; data were extracted from 61 original articles.</p></div><div><h3>Results</h3><p>On average, ILD in these patients progressed by 33.7% over time. Patients with progressive pulmonary fibrosis had a similar 3.7-year median survival as those with idiopathic pulmonary fibrosis. Mortality was markedly increased (hazards ratio 3.29; 95% CI 2.76–3.82). A progressive course was seen in 34% of scleroderma (SSc) related ILD cases. Six interferon-induced proteins and a proteomic profile of 12 biomarkers were used to predict progression and response to treatment. The INBUILD and SENSCIS studies that assessed the effectiveness of nintedanib effectiveness revealed a reduced decrease in forced vital capacity. Progression in rheumatoid arthritis (RA) related ILD ranges from 38% to 50%. Control of RA disease activity and use of antifibrotics benefit the lungs.</p></div><div><h3>Conclusion</h3><p>A significant proportion of patients with CTD-ILD have progressive lung disease, with the corresponding adverse mortality effects. The majority of the data regarding CTD-ILD are from cohorts of patients with RA-ILD and SSc-ILD, in which antifibrotics and concurrent immunosuppressive treatments have been effective. There is not enough information available on other autoimmune disorders to draw any firm conclusions regarding progression rates or treatment effects.</p></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"31 ","pages":"Pages S82-S93"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139295631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fibromyalgia and associated factors in patients with axial spondyloarthritis: The effect of fibromyalgia on disease activity","authors":"İpek Türk ,&nbsp;Mehmet Ali Aşık ,&nbsp;Şerife Şeyda Zengin Acemoğlu ,&nbsp;Gizem Varkal ,&nbsp;İlker Ünal","doi":"10.1016/j.rcreu.2022.10.001","DOIUrl":"10.1016/j.rcreu.2022.10.001","url":null,"abstract":"<div><h3>Introduction/Objective</h3><p>The aim of this study was to investigate the frequency of fibromyalgia (FM) in axial spondyloarthritis (ax-SpA) patients using the current FM diagnostic criteria (2016 Revised Fibromyalgia Diagnostic Criteria). Additionally, we aimed to investigate the relationship between FM severity and disease activity, functional status, and quality of life (QoL).</p></div><div><h3>Materials and methods</h3><p>Disease activity, functional disability and QoL were evaluated. FM severity was measured with the fibromyalgia impact questionnaire (FIQ).</p></div><div><h3>Results</h3><p>One hundred and three patients with ax-SpA (55.3% female; mean age 44<!--> <!-->±<!--> <!-->10.85 years) were included. FM was detected in 49.5% of the patients. While FM was detected in 71% of patients with a history of peripheral arthritis, FM was present in 59.2% of patients without (<em>p</em><span> = 0.009). FM-ax-SpA patients showed higher disease activity except for C-reactive protein; functional status and QoL were statistically worse in patients with FM-SpA. Significant positive correlations were found between FIQ and disease activity, functional disability and QoL (</span><em>p</em> <!-->&lt;<!--> <!-->.001).</p></div><div><h3>Conclusions</h3><p>The most effective features associated with the presence of FM were detected as gender and a history of peripheral arthritis. Presence of FM may cause an overestimation of disease activity, FM severity correlates with disease activity.</p></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"31 2","pages":"Pages 159-165"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45947523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The lung as a target and as an initiator of rheumatoid arthritis-associated immunity: Implications for interstitial lung disease","authors":"Malena Loberg Haarhaus,&nbsp;Lars Klareskog","doi":"10.1016/j.rcreu.2023.09.006","DOIUrl":"10.1016/j.rcreu.2023.09.006","url":null,"abstract":"<div><p>Interstitial lung disease (ILD) is a serious extra-articular co-morbidity in rheumatoid arthritis (RA) patients and accounts for a substantial part of the increased mortality in RA. In this review, we describe how environmental and lifestyle factors interact with genetic variants in the HLA genetic locus in triggering RA-specific antibodies against post-translationally modified, mainly citrullinated proteins (ACPA), which are associated with an increased risk of ILD. The same environmental risk factors, i.e. exposure to noxious agents such as smoke to the lungs contribute additionally to the emergence of RA ILD as does long-lasting high disease activity and an additional ILD-specific genetic risk variant related to mucus formation (MUC5B). Options for prevention and therapy of RA ILD resulting from this so far incomplete knowledge of its pathophysiology are expanding. The most obvious option is to address modifiable environmental risk factors, such as smoking and exposure to other noxious agents affecting the lungs. The second option is to reduce the inflammatory activity of RA; here different anti-rheumatic therapies appear to have differential effects on ILD development. The third and novel option is to use anti-fibrotic therapy which may reduce the development of RA ILD but has not yet been shown to revert existing fibrosis. The main conclusion concerning the clinical handling of RA ILD is therefore an early awareness of the risk for RA ILD combined with active measures to reduce modifiable environmental/lifestyle factors and use optimal anti-rheumatic therapies for early and sustained reduction of disease activity. These actions should be combined with a preparedness to use anti-fibrotic therapy for patients at high risk for ILD despite previous risk reduction efforts.</p></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"31 ","pages":"Pages S74-S81"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139540635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Myositis-associated interstitial lung disease","authors":"Siamak Moghadam-Kia,&nbsp;Chester V. Oddis","doi":"10.1016/j.rcreu.2023.09.003","DOIUrl":"https://doi.org/10.1016/j.rcreu.2023.09.003","url":null,"abstract":"<div><h3>Introduction/Objective</h3><p>To review the epidemiology, general clinical aspects and diagnosis, impact on morbidity and mortality, and general treatment approaches for myositis-associated ILD.</p></div><div><h3>Materials and methods</h3><p>The relevant literature was reviewed.</p></div><div><h3>Results</h3><p>The clinical, radiographic, and histopathological features of interstitial lung disease (ILD) in idiopathic inflammatory myopathies (IIM) are similar to idiopathic ILD. Patients with a known diagnosis of myositis require prompt clinical evaluation including the determination of myositis-associated autoantibodies. Patients possessing autoantibodies associated with ILD or those with any pulmonary symptoms should undergo a pulmonary function test and high-resolution CT (HRCT) scanning of their lungs.</p></div><div><h3>Conclusion</h3><p>Despite the lack of placebo-controlled trials, systemic glucocorticoids are considered the mainstay of initial treatment of myositis-associated ILD. Glucocorticoid-sparing agents are often concomitantly administered, particularly in patients with severe disease. The first-line conventional immunosuppressive drugs include either mycophenolate mofetil or azathioprine. If these agents fail or if the pulmonary features are severe or rapidly progressive, then more aggressive immunosuppressive or immunomodulatory therapy including cyclophosphamide, tacrolimus<span> or cyclosporine, rituximab, IVIg, or tofacitinib can be considered. Further investigations are required to assess the role of novel therapies in the treatment of myositis-associated ILD.</span></p></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"31 ","pages":"Pages S154-S165"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140344055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An overview of screening, treatment, and next steps in research in rheumatoid arthritis interstitial lung disease","authors":"Scott M. Matson ,&nbsp;Joyce S. Lee","doi":"10.1016/j.rcreu.2023.07.002","DOIUrl":"10.1016/j.rcreu.2023.07.002","url":null,"abstract":"<div><p><span><span><span>Rheumatoid arthritis associated </span>interstitial lung disease (RA-ILD) has significant clinical impact on patients due to increased morbidity and mortality. Understanding the progression of ILD </span>in patients<span> with RA from when asymptomatic to clinical progression and the clinical, genetic, and novel markers associated with disease progression is an important step in altering the natural history of ILD in patients with RA. We review the natural history and </span></span>epidemiology<span> of RA-ILD, with a focus on Latin-American epidemiology in RA-ILD. Additionally, we discuss unique features of RA-ILD compared to other forms of ILD, early disease detection, and current concepts in treatment.</span></p></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"31 ","pages":"Pages S26-S34"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44739441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of an ultrasound set for early diagnosis of rheumatoid arthritis: First steps","authors":"Ben Abdelghani Kawther ,&nbsp;Miladi Saoussen ,&nbsp;Mahmoud Ines ,&nbsp;Ajlani Houda ,&nbsp;Bahiri Rachid ,&nbsp;Haddouche Assia ,&nbsp;Harifi Ghita ,&nbsp;Slimani Samy ,&nbsp;Laatar Ahmed","doi":"10.1016/j.rcreu.2023.02.009","DOIUrl":"10.1016/j.rcreu.2023.02.009","url":null,"abstract":"<div><h3>Introduction/Objective</h3><p>Early diagnosis of rheumatoid arthritis (RA) can improve the prognosis of the disease by reducing joint destruction and achieving a better rate of remission. Musculoskeletal ultrasound (US) has become a potent tool to detect synovitis and erosions. However, until now, there has been a lack of consensus on the US scoring system to help in diagnosing RA early. The purpose of our study was to elaborate a US set suitable for classifying RA patients with inflammatory arthralgia or expressing synovitis and who did not satisfy ACR/EULAR criteria, called “USSRA” (UltraSound Set for Rheumatoid Arthritis).</p></div><div><h3>Materials and methods</h3><p>A multistep study was conducted. A preliminary set of joints, tendons, and erosions to include in the USSRA were identified through a deep literature screening. The final step of this study was the validation of the final set by international experts in US using a Delphi process.</p></div><div><h3>Results</h3><p>The preliminary set included 20 joints, 16 tendons, and 8 erosion sites for assessment. After the Delphi process, the changes were to add an assessment of two additional wrist joints and remove one. As for the tendons, two sites were removed from the final set. No changes were proposed for the section erosions. The elementary lesions and scoring system were clarified. The final USSRA forms include 18 joints, 12 tendons, and 8 sites of erosion.</p></div><div><h3>Conclusion</h3><p>The USSRA is a novel diagnostic tool proposed for detecting early RA in routine practice. The next step will be to assess the reliability of this set in a patient-based exercise.</p></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"31 2","pages":"Pages 178-184"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41609672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complicación hematológica con impacto pulmonar en una paciente con síndrome de Sjögren","authors":"Laura Gallego ,&nbsp;Jhon Buitrago ,&nbsp;Diana Guavita-Navarro ,&nbsp;Jairo Cajamarca-Barón ,&nbsp;Ana María Arredondo ,&nbsp;José Fernando Polo Nieto ,&nbsp;Juan Pablo Castañeda-González ,&nbsp;Alejandro Escobar","doi":"10.1016/j.rcreu.2023.02.006","DOIUrl":"10.1016/j.rcreu.2023.02.006","url":null,"abstract":"<div><p>Sjögren's Syndrome (SS) is an autoimmune pathology with glandular and/or extraglandular compromise, secondary to the infiltration of lymphoid cells. The clinical course varies depending on genetic susceptibility, comorbidities, patient's age, and environmental risk factors. Lymphoid proliferation and differentiation are key factors in the progression of SS to haematological malignancies or amyloidosis. Amyloidosis is a secondary entity to the aberrant accumulation of soluble plasma proteins, derived from chronic infectious, inflammatory, neoplastic and haematolymphoid processes. The clinical manifestations vary and depend on the constitutive protein and the age of the patient; and may have glandular or extraglandular, local, or systemic compromise. Among the affected organs, pulmonary involvement poses a diagnostic and therapeutic challenge due to its variable course and clinical manifestation. The following is a case report of a woman over 70 years old, with SS and amyloidosis with glandular and extra glandular manifestations at pulmonary level.</p></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"31 2","pages":"Pages 259-263"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49565653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is it possible to optimize biologic therapy in patients with psoriasis?","authors":"Ángela María Londoño-García ,&nbsp;María Fernanda Suárez-Giraldo ,&nbsp;Lina María Colmenares-Roldán ,&nbsp;Juliana Madrigal-Cadavid ,&nbsp;Jorge Estrada ,&nbsp;Paulo Giraldo ,&nbsp;Daniel Jaramillo-Arroyave","doi":"10.1016/j.rcreu.2022.10.002","DOIUrl":"10.1016/j.rcreu.2022.10.002","url":null,"abstract":"<div><h3>Introduction/Objective</h3><p>The purpose of this study was to evaluate patients in clinical remission of psoriasis for at least for one year, who maintained therapeutic goals after initiating optimization of biologic therapy.</p></div><div><h3>Materials and methods</h3><p>A descriptive, observational study was conducted on patients with a diagnosis of moderate–severe psoriasis in treatment with biologic therapy who were started on optimization of biologic therapy.</p></div><div><h3>Results</h3><p><span>A total of 29 patients started therapeutic optimization, of these, 27 patients were in the target range with absolute PASI less than 3. Only one patient failed therapeutic optimization with final PASI 3.6 and there was a case of a patient who lost continuity of management due to an accident and had a final PASI 3.8. Most of the patients were male, with an average age of 53 years, married, employed, residing in urban areas, with psoriasis of more than ten years of evolution, without associated morbidities, and without previous biologic treatment, the most frequently used being etanercept and </span>adalimumab.</p></div><div><h3>Conclusion</h3><p>Optimizing biologic therapy in patients with moderate–severe psoriasis may be viable. We seek to share this experience to propose a protocol to reduce the possibility of adverse events due to the prolonged use of this type of therapy, preserving clinical response and reducing costs to the health system.</p></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"31 2","pages":"Pages 166-170"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48121994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Measurement of health-related quality of life in patients with interstitial lung disease and autoimmune diseases","authors":"Claudia Mora ,&nbsp;Alirio Rodrigo Bastidas Goyes ,&nbsp;Lina Paola Fajardo Muriel ,&nbsp;Cristian Felipe Rodríguez Yasno","doi":"10.1016/j.rcreu.2023.08.005","DOIUrl":"10.1016/j.rcreu.2023.08.005","url":null,"abstract":"<div><p><span>Autoimmune diseases comprise a wide and diverse group of diseases, each with its own specific complications, and with common complications such as pulmonary involvement. Lung involvement is extensive and one of its complications is interstitial lung disease, which varies widely within each of the autoimmune diseases. Health-related </span>quality of life<span> is defined as all those aspects that reflect the impact of the disease and the perception of disability and daily functionality of the patient. Even though this concept is subjective, health researchers have sought to define it to serve as a tool in the evaluation of interventions in subjects with different types of pathologies, so much so that it has become a main outcome in program evaluation and clinical research. To date, we are not aware of tools designed with the objective of measuring quality of life specifically in lung involvement due to interstitial lung disease related to autoimmune diseases. The objective of this review will be to further explore the available information on the measurement of quality of life in these patients.</span></p></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"31 ","pages":"Pages S67-S73"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135510586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A woman with fever, arthralgia, and chronic urticaria","authors":"Edwin Uriel Suárez ,&nbsp;Teresa Arquero ,&nbsp;Fernando Tornero ,&nbsp;Sheila Recuero","doi":"10.1016/j.rcreu.2022.06.002","DOIUrl":"10.1016/j.rcreu.2022.06.002","url":null,"abstract":"","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"31 1","pages":"Pages 138-140"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48128765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}